Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L1210/DTIC antigenic subline: studies at the clone level.

O Marelli, G Canti, P Franco

    European Journal of Cancer & Clinical Oncology
    |November 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A spectral- topological network signature of drug-resistant epilepsy: a phase 1-2 study on resting-state EEG-based diagnostic biomarkers of drug resistance.

    NeuroImage. Clinical·2026
    Same author

    Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in Epilepsy.

    European journal of neurology·2025
    Same author

    Epilepsy and Employment in Europe: A Systematic Review of Literature.

    European journal of neurology·2025
    Same author

    Altered neural avalanche spreading in people with drug-resistant epilepsy<sup>✰</sup>.

    NeuroImage·2025
    Same author

    Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study.

    Frontiers in neurology·2025
    Same author

    How autistic women are aware of their body and take care of their health? Focus on menstruation cycles and gynecological care.

    La Clinica terapeutica·2024

    Treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) induced new, heritable tumor antigens in mice. These novel antigens, expressed by L1210 leukemia sublines, were recognized by the immune system, suggesting potential for targeted cancer therapies.

    Area of Science:

    • Oncology
    • Immunology
    • Cancer Research

    Background:

    • The anti-tumor agent 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) is used in cancer treatment.
    • DTIC treatment induces new antigenic specificities in murine tumor cells.
    • These induced antigens are heritable and maintained after DTIC withdrawal.

    Purpose of the Study:

    • To investigate the immunogenicity and antigenic properties of DTIC-induced murine leukemia L1210 sublines.
    • To characterize the antigens expressed by DTIC-treated L1210 leukemia clones.
    • To assess the immune system's recognition of these novel tumor-associated antigens.

    Main Methods:

    • Selection and study of seven clones from L1210/DTIC murine leukemia.
    • In vivo assessment of clone immunogenicity using syngenic mice.

    Related Experiment Videos

  • In vitro lymphocyte stimulation and cytotoxicity assays using L1210/DTIC and its clones.

    • Main Results:

    • Three of seven L1210/DTIC clones exhibited increased immunogenicity in vivo.
    • DTIC-induced sublines and clones were recognized and lysed by lymphocytes primed with L1210/DTIC.
    • Specific lymphocyte responses indicated that each clone expressed distinct sets of antigens, with some shared antigens among sublines.

    Conclusions:

    • DTIC treatment of L1210 leukemia induces a limited number of distinct antigens expressed across different cell sublines.
    • The induced antigenic specificities are heritable and recognized by the host immune system.
    • These findings highlight the potential of DTIC-induced antigens in cancer immunotherapy.